Although a cohort analysis of the association between these mRNAs and gefitinib resistance is not currently available, but our analysis of OS showed that both the up-regulation of ABCC8, ABCD1, BDNF, BIRC5, CDK4, CDKN2A, DLG4, GRIN2B, IGF1R, MET, MLST8, NFKB2, NGFR, NOTCH3, RASA4, SLC2A4, SLC3A2, SLC12A3, TP53, TP73, VEGFA, and the down-regulation of ABL2, AKT2, CDK15, CFTR, DNMT3A, EFNA5, ERBB3, GLI3, ICAM1, JRK, KDM6A, LAMA3, LAMB1, LTBP1, MAP3K12, PFKFB3, RBBP4, SP4, TIMP3 were associated with poor prognosis of patient with lung cancer. Here, MET is linked to lung carcinoma.